Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review

Abstract

Aim With industrialization and spread of the westernized lifestyle, the number of people affected by non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) is growing rapidly in China; this has become a major public health concern. To better understand the burden and characteristics of NAFLD/NASH in China, we aim to perform a narrative review of the literature published in this field. Materials and Methods We carried out a comprehensive electronic search of five English‐language and three Chinese‐language databases, to identify studies regarding NAFLD or NASH published from inception to November 30, 2022. Epidemiological studies of NAFLD/NASH in China were particularly noticed and summarized. We also searched the http://www.clinicaltrials.gov and http://www.chictr.org.cn websites for the registered trials on the treatment of the disease led by Chinese investigators or located in China. Results The increasing rate of NAFLD prevalence in China is strikingly high, reaching more than twice that in western countries. The prevalence of NAFLD is nearly 30% of the general Chinese population, making it the leading cause of chronic liver diseases. The prevalence of NAFLD/NASH varies between provinces/regions, age groups, sexes, and individuals with different metabolic profiles. NAFLD co‐exists in many Chinese patients with chronic hepatitis B. Since 2020, more Chinese studies have used the term metabolic‐associated fatty liver disease (MAFLD), emphasizing the underlying metabolic disorders that occur concurrently with this disease. Several clinical trials involving lifestyle interventions, antidiabetic drugs, or traditional Chinese medicines, registered by Chinese investigators, have been completed or are ongoing. Moreover, several innovative targeted therapies developed in China are revolutionizing the treatment of NAFLD/NASH. Conclusions NAFLD has cast a heavy burden on the Chinese healthcare system. Chinese scholars are making efforts to achieve the optimal management of this disease.

Vitamin D improves hepatic steatosis in NAFLD via regulation of fatty acid uptake and β-oxidation

“…Furthermore, a low VD level has been identified as an independent risk factor for NAFLD ( 65 ). In general, the prevalence of NAFLD is higher in men than women, and it is higher in postmenopausal women than premenopausal women, which is attributed to the hepatic protective effect of estradiol ( 66 , 67 ). Thus, we adjusted the effect of age and gender by matching and multiple logistic regression.…”

Association between Urinary Haloacetic Acid Concentrations and Liver Injury among Women: Results from the Tongji Reproductive and Environmental (TREE) Study

“… 4 In China, the prevalence of NAFLD is nearly 30% and has increased by 10% from 2008 to 2018. 5 , 6 The increasing prevalence of NAFLD has been associated with greater risks of type 2 diabetes, 7 cardiovascular disease, 8 metabolic syndrome, 9 chronic kidney disease, 10 and cancer. 11 Therefore, it is essential to identify potentially modifiable risk factors for liver injury and NAFLD to enhance prevention strategies.…”

Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic

“…In China, the rate of MASLD prevalence is escalating at an alarming pace, reaching more than twice that of western countries. In the general population of China, the prevalence of MASLD is close to 30%, which is the primary cause of chronic liver disease, and there are also differences among individuals in different provinces and regions, age groups, sexes, and metabolic situations ( 9 ). In the past two decades, the high prevalence of MASLD, along with the associated mortality rates for liver and extrahepatic disorders, has posed significant threats to human well-being, imposing substantial social and economic burdens on affected families and nations ( 10 ).…”